S&P Global beats Q3 estimates, raises guidance, and plans divestitures amid strong ratings demand and profitability.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
S&P Global beats Q3 estimates, raises guidance, and plans divestitures amid strong ratings demand and profitability.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.